<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4223">
  <stage>Registered</stage>
  <submitdate>18/06/2013</submitdate>
  <approvaldate>18/06/2013</approvaldate>
  <nctid>NCT02010242</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria</studytitle>
    <scientifictitle>A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GSN000200</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus With Diabetic Nephropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GKT137831
Treatment: drugs - Placebo

Experimental: GKT137831 - GKT137831 100 mg capsules twice a day

Placebo Comparator: Placebo - Placebo capsule twice a day


Treatment: drugs: GKT137831
1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment

Treatment: drugs: Placebo
1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Albuminuria - Change in UACR from baseline to Visits 9, 10, and 11 (i.e. weeks 8, 10 and 12 of the treatment period, respectively)</outcome>
      <timepoint>Visits 4 (week -2), 5 (week 0), 6 (week 2), 7 (week 4), 8 (week 6), 9 (week 8), 10 (week 10), 11 (week 12), and 12 (week 16)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glucose metabolism - Change in HOMA-B, HOMA-IR and HbA1c from baseline</outcome>
      <timepoint>Visits 5 (week 0), 8 (week 6), and 11 (week 12)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Male or female aged 18 to 80 years

          -  History of type 2 diabetes, defined as fasting plasma glucose =7.0 mmol/L (126 mg/dL)
             or a glycated hemoglobin (HbA1c) &gt;6.5% (48 mmol/mol) on at least 2 occasions prior to
             screening.

          -  Albuminuria defined as a UACR of 300 to 3500 mg/g.

          -  An eGFR =30 mL/min/1.73 m2, as calculated by the CKD-EPI formula.

          -  Must be taking an ACEI or an ARB for at least 6 weeks prior to the first screening
             visit (Visit 1) and during the screening period. The dose must have been stable for at
             least 4 weeks prior to the first screening visit (Visit 1). Combination therapy
             associating an ACEI and an ARB is not permitted.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of type 1 diabetes

          -  Any other non-diabetic kidney disease(s) except for hypertensive nephropathy which is
             acceptable.

          -  Diagnostic or interventional procedure requiring a contrast agent within 4 weeks of
             the first screening visit (Visit 1) or planned during the study.

          -  History of renal transplant or planned renal transplant during the study.

          -  A history of acute renal dialysis or acute kidney injury (defined according to the
             Kidney Disease: Improving Global Outcomes [KDIGO] definition) within 12 weeks of the
             first screening visit (Visit 1)

          -  HbA1c level &gt;11% (97 mmol/mol).

          -  History of hypothyroidism requiring hormone replacement therapy.

          -  History of active cardiovascular disease

          -  A personal or family history of long QT syndrome.

          -  Administration of any investigational product within 30 days or within 5 half-lives of
             the investigational agent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Marrondah ECRU - East Ringwood</hospital>
    <hospital>Deakin University school of medicine - Geelong</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <hospital>Baker Institute - Melbourne</hospital>
    <hospital>Captain Stirling Medical Centre - Nedlands</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3135 - East Ringwood</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3081 - Heidelberg</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Huzova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Novy Bydzov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aschaffenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Elsterwerda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Staszow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genkyotex Innovation SAS</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic
      complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4
      inhibitor.

      The primary objective of this study is to evaluate the efficacy of oral GKT137831 in patients
      with residual albuminuria despite maximal inhibition of the renin angiotensin aldosterone
      system.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02010242</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Philippe Wiesel, MD</name>
      <address>Genkyotex Innovation SAS</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>